Predicting prostate cancer many years before diagnosis: how and why?
- First Online:
Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis and overtreatment. One way to shift the ratio of benefits to harm is to focus on men at highest risk, who have more to benefit than average. Neither family history nor any of the currently identified genomic markers offer sufficient risk stratification for practical use. However, there is considerable evidence that the levels of PSA in blood are strongly prognostic of the long-term risk of aggressive prostate cancer. Specifically, it is difficult to justify continuing to screen men aged 60 or older if they have a PSA less than 1 or 2 ng/ml; for men 45–60, intervals between PSA tests can be based on PSA levels, with 2–4-year retesting interval for men with PSA of 1 ng/ml or higher, and tests every 6–8 years for men with PSA <1 ng/ml. Men with the top 10% of PSAs at a young age (PSA ~1.5 ng/ml or higher below 50) are at particularly high risk and should be subject to intensive monitoring.
KeywordsProstatic neoplasms Early detection of cancer Prostate-specific antigen
- 1.Thompson IM, Lucia MS, Tangen CM (2007) Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: “what has been will be again, what has been done will be done again; there is nothing new under the sun.” ECCLESIASTES 1:9. Int J Epidemiol 36(2):287–289. doi:10.1093/ije/dym056 PubMedCrossRefGoogle Scholar
- 3.Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Gronberg H (2009) Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 69(14):1565–1572. doi:10.1002/pros.21002 PubMedCrossRefGoogle Scholar
- 8.Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H (2006) Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 52(2):235–239. doi:10.1373/clinchem.2005.050641 PubMedCrossRefGoogle Scholar
- 9.Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117(6):1210–1219. doi:10.1002/cncr.25568 PubMedCrossRefGoogle Scholar
- 10.Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H (2010) Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (Clin Res Ed) 341:c4521. doi:10.1136/bmj.c4521 CrossRefGoogle Scholar
- 11.Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi:10.1056/NEJMoa0810084 PubMedCrossRefGoogle Scholar
- 14.Bul M, van Leeuwen PJ, Zhu X, Schroder FH, Roobol MJ (2011) Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 59(4):498–505. doi:10.1016/j.eururo.2011.01.001 PubMedCrossRefGoogle Scholar
- 18.Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358(9):910–919. doi:10.1056/NEJMoa075819 PubMedCrossRefGoogle Scholar